KristiJoMcIntyreMD

Oncology • Dallas, TX

Physician

Join to view full profile

Dr. McIntyre is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McIntyre's full profile

Already have an account?

Office
8196 Walnut Hill Ln
Ste 100
Dallas, TX 75231
Phone+1 214-739-4175

Fax+1 214-987-4161

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1988 - 1989
University of Mississippi Medical CenterFellowship, Hematology and Medical Oncology, 1986 - 1988
University of Mississippi Medical CenterResidency, Internal Medicine, 1982 - 1986
Tulane University School of MedicineClass of 1982

Certifications & Licensure

TX State Medical License 1991 - 2026
LA State Medical License 1982 - 2004
FL State Medical License 1990 - 2002
MN State Medical License 1989 - 1995
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Super Doctor SuperDoctors.com

Clinical Trials

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Start of enrollment: 2010 Dec 02
Completed
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 3
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2013 Mar 07
Completed
Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
Completed
Phase 2
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients Start of enrollment: 2014 Mar 08
Completed
Phase 2
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Start of enrollment: 2018 Oct 31
COMPLETED
PHASE2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2020 Sep 03
RECRUITING
PHASE2, PHASE3
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer Start of enrollment: 2021 May 10
TERMINATED
PHASE3
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer Start of enrollment: 2021 Oct 04
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

5 citations
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
Sara M Tolaney, Valentina Guarneri, Jae Hong Seo, Josefina Cruz, Miguel Henriques Abreu
European Journal of Cancer. 2024-03-01
63 citations
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase I...
Shannon N Westin, Kathleen Moore, Hye Sook Chon, Jung-Yun Lee, Jessica Thomes Pepin
Journal of Clinical Oncology. 2024-01-20
120 citations
Evaluation of cell-free DNA approaches for multi-cancer early detection.
Arash Jamshidi, Minetta C Liu, Eric A Klein, Oliver Venn, Earl Hubbell
Cancer Cell. 2022-12-12

Press Mentions

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01February 15th, 2024